Dr Reddy’s Acquires Nicotinell In A £500m Deal

The Acquistion Marks Another Step In The Company’s Diversified Strategy

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

Reddy's logo
• Source: Shutterstock

Dr Reddy’s Laboratories has acquired rights to Haleon’s nicotine replacement therapy product portfolio outside of the US as part of a £500m ($632m) deal, marking a further expansion of Dr Reddy’s beyond pharmaceuticals.

More from Deals

More from Business

Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars

 

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

M&Ms And PBMs: Sandoz CEO Talks Antibiotics And Ustekinumab

 
• By 

At the J.P. Morgan Healthcare Conference in San Francisco, Sandoz CEO Richard Saynor commented on the “offensively” low pricing for antibiotics in the US – “less than a packet of M&Ms” – while also revealing that the firm has struck a deal with a US PBM for its Samsung Bioepis-partnered Pyzchiva ustekinumab biosimilar to Stelara.

Xentria Ramps Up Clinical Focus On Biosimilars In 2025

 
• By 

Adding to five new clinical trials launched in 2024, Xentria is doubling down on its ambitions in the biosimilars arena with up to six further studies in the coming year.